The identification of Zika virus (ZIKV) from the amniotic fluid of two fetuses with severe central nervous system (CNS) abnormalities in 2016 was the first evidence of vertical transmission of ZIKV [1] . ZIKV has since been established as the etiology of congenital Zika syndrome (CZS), characterized in its most severe form by microcephaly and severe CNS malformations, with rates of adverse pregnancy outcome exceeding 40% in some studies [2] . Prenatal diagnosis of CZS informs management of the pregnancy and care of the ZIKV-exposed infant. However, the optimal method of prenatal screening and diagnosis of ZIKV infection remains undetermined. Testing is complicated by the asymptomatic course of most infections, the narrow window of viral RNA detection in maternal serum and/or urine, and limitations in maternal serologic testing due to delayed seroconversion, and false positive results from cross-reactivity with other flaviviruses [2, 3] . Amniocentesis, the gold standard for prenatal diagnosis of vertical transmission in other infections, has not been routinely recommended in cases of suspected CZS, due to the invasive nature of the test (which carries a small risk of pregnancy complications), the limited data available to guide the timing of testing and interpretation of results, and limited therapeutic options [3] .
Available data on the performance of ZIKV detection in amniotic fluid has been limited to isolated case reports and small case series of confirmed CZS that have reported a total of 27 cases [1, [4] [5] [6] [7] [8] [9] [10] [11] .
Here, we report on a prospective cohort of patients referred for suspected ZIKV infection during the Table. The median gestational age at the time of amniocentesis was 26 weeks (range 18 to 34). Eight mothers reported symptoms of ZIKV infection. For symptomatic cases, the median elapsed time from suspected infection to amniocentesis was 16.5 weeks (range 10 to 27). There were 7 cases of ZIKV detected by RT-PCR in amniotic fluid, ranging from 10 to 19 weeks after suspected infection. There were two other cases of TORCH infection (CMV and toxoplasmosis, respectively), with amniocentesis detecting congenital infection in 56% of pregnancies. Eight patients consented for karyotype testing, of which one case confirmed trisomy 18.
In this cohort of fetuses with CNS abnormalities, amniocentesis detected 7/9 (78%) of CZS cases. Two additional cases were diagnosed through postnatal evaluation and testing of the neonate: Case 4 by placenta and fetal cord blood, and Case 11 by placenta, neonatal blood, and PCR of cerebrospinal fluid.
Of the two CZS cases that were not detected on amniocentesis, the elapsed times from suspected infection to amniotic fluid testing were 27 weeks and >17 weeks. There were three patients who were found to be positive for CZS by amniocentesis but had PCR-negative postnatal samples. These included: Case 5 (negative neonatal blood, urine, placenta, and cerebrospinal fluid), Case 9 (negative neonatal blood and cord blood), and Case 15 (negative cord blood, urine, placenta, and cerebrospinal fluid).
Detailed results of postnatal outcomes (evaluation, neuroimaging, and relevant tests) are reported in the Supplemental Table. Overall, there were 2 cases of stillbirth (13%) and 4 cases of neonatal death (25%), with a perinatal/ postnatal death rate of 38% in this high-risk cohort.
Discussion
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To our knowledge, this is the first prospective cohort examining the role of amniocentesis as a diagnostic tool in cases of suspected ZIKV infection. In our cohort of 16 fetuses with CNS abnormalities on ultrasound during the 2016 ZIKV epidemic in Rio de Janeiro, there were 9 confirmed cases of CZS.
Amniocentesis had a ZIKV detection rate of 63% (7/9).
The majority of cases were likely infected in the first trimester based on reported symptoms, and only two patients had maternal ZIKV testing by RT-PCR at the time of symptoms-all with negative results. All patients were referred for CNS abnormalities on ultrasound during the epidemic, where there was high risk of exposure to ZIKV and a high potential for CZS. Amniocentesis for genetics or suspected TORCH infection is not commonly performed in Brazil, as it is not routinely accepted by patients due to fear of pregnancy loss or other complications, such as infection or premature rupture of membranes, and the lack of pregnancy options.
As of July 2018, review of the literature found a total of 27 cases reported on the use amniocentesis for the diagnosis of ZIKV infection. However, we found no prospective reports, and determination of the sensitivity and specificity of ZIKV PCR as a diagnostic tool could not be determined. Our results suggest that in the setting of ultrasound abnormalities and high risk of ZIKV exposure, amniocentesis is helpful as a diagnostic tool to aid in prenatal diagnosis, pregnancy care, and optimization of pediatric support.
The optimal time to perform amniocentesis remains to be determined. Meaney-Delman et al. detected ZIKV in amniotic fluid as early as 3 weeks after infection [12] . The window for molecular detection of ZIKV is longer than the usual time of active viral shedding in maternal blood or urine, which is between 1-4 weeks in pregnant women, although prolonged viremia is possible [2] . We successfully detected well as in other reports [7, 8] . In cases of high suspicion for CZS, testing of the placenta and the infant after birth is a critical component of comprehensive evaluation, especially as knowledge of the full spectrum of findings in CZS continues to be elucidated.
One limitation of our study is generalizability to cases of suspected ZIKV infection and normal ultrasound. Prospective studies in this population are urgently needed. Additionally, this cohort does not address the timing of vertical transmission from mother to fetus or the timing of development of ultrasound findings, as the majority of women were not tested at the time of symptoms, did not undergo a standardized protocol for ultrasound screening, and were not referred until they had an abnormal ultrasound. Women in our cohort had very high risk pregnancies, with serious CNS fetal defects, leading to fetal or neonatal demise in almost 40% of cases (2 stillbirths due to Zika and toxoplasmosis, 2 of 4 neonatal deaths due to Zika or chromosomal abnormalities, and 2 others of unknown etiology). Furthermore, greater numbers of cases with varying degrees of fetal disease severity are needed to more accurately determine sensitivity and specificity, as well the the effect of timing with respect to infection.
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This study supports the utility of amniotic fluid testing for the diagnosis of vertical transmission of ZIKV.
A diagnostic result was determined in 63% of cases, all of whom presented outside the established window for maternal ZIKV testing, and three of which had PCR-negative postnatal testing. Confirmatory testing of CZS is important for prenatal counseling, informed decision-making for the pregnancy, as well as delivery planning and care of the affected infant. 
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